DK2825640T3 - Batches af rekombinant adenovirus med ændrede terminale ender - Google Patents
Batches af rekombinant adenovirus med ændrede terminale ender Download PDFInfo
- Publication number
- DK2825640T3 DK2825640T3 DK13708445.5T DK13708445T DK2825640T3 DK 2825640 T3 DK2825640 T3 DK 2825640T3 DK 13708445 T DK13708445 T DK 13708445T DK 2825640 T3 DK2825640 T3 DK 2825640T3
- Authority
- DK
- Denmark
- Prior art keywords
- adenovirus
- recombinant
- sequence
- recombinant adenovirus
- particles
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title claims description 230
- 239000002773 nucleotide Substances 0.000 claims description 55
- 125000003729 nucleotide group Chemical group 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 51
- 239000002245 particle Substances 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 38
- 241000598171 Human adenovirus sp. Species 0.000 claims description 28
- 108700019146 Transgenes Proteins 0.000 claims description 18
- 238000000746 purification Methods 0.000 claims description 16
- 238000003306 harvesting Methods 0.000 claims description 12
- 241000990167 unclassified Simian adenoviruses Species 0.000 claims description 10
- 238000010369 molecular cloning Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 230000001902 propagating effect Effects 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 description 97
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 84
- 239000013598 vector Substances 0.000 description 57
- 241000700605 Viruses Species 0.000 description 45
- 108090000623 proteins and genes Proteins 0.000 description 30
- 230000010076 replication Effects 0.000 description 24
- 241001135569 Human adenovirus 5 Species 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 19
- 241000282414 Homo sapiens Species 0.000 description 19
- 230000003612 virological effect Effects 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 16
- 239000000427 antigen Substances 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 13
- 230000002950 deficient Effects 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 229960005486 vaccine Drugs 0.000 description 11
- 239000002671 adjuvant Substances 0.000 description 9
- 230000000890 antigenic effect Effects 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 239000003599 detergent Substances 0.000 description 9
- 230000004927 fusion Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000002163 immunogen Effects 0.000 description 8
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 238000001415 gene therapy Methods 0.000 description 7
- 101710163270 Nuclease Proteins 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 5
- 108700039887 Essential Genes Proteins 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000000644 propagated effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241001217856 Chimpanzee adenovirus Species 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108090000565 Capsid Proteins Proteins 0.000 description 3
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 101710145505 Fiber protein Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101710094396 Hexon protein Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 101710173835 Penton protein Proteins 0.000 description 3
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 238000011210 chromatographic step Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 241000701242 Adenoviridae Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 238000007399 DNA isolation Methods 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 101710088335 Diacylglycerol acyltransferase/mycolyltransferase Ag85A Proteins 0.000 description 2
- 101710088334 Diacylglycerol acyltransferase/mycolyltransferase Ag85B Proteins 0.000 description 2
- 241001115402 Ebolavirus Species 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 101710192606 Latent membrane protein 2 Proteins 0.000 description 2
- 241001115401 Marburgvirus Species 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 101710109576 Terminal protein Proteins 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 108700010877 adenoviridae proteins Proteins 0.000 description 2
- 229940021704 adenovirus vaccine Drugs 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
- 229940001007 aluminium phosphate Drugs 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- 238000009126 molecular therapy Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- -1 n Species 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- AWXGSYPUMWKTBR-UHFFFAOYSA-N 4-carbazol-9-yl-n,n-bis(4-carbazol-9-ylphenyl)aniline Chemical compound C12=CC=CC=C2C2=CC=CC=C2N1C1=CC=C(N(C=2C=CC(=CC=2)N2C3=CC=CC=C3C3=CC=CC=C32)C=2C=CC(=CC=2)N2C3=CC=CC=C3C3=CC=CC=C32)C=C1 AWXGSYPUMWKTBR-UHFFFAOYSA-N 0.000 description 1
- 206010001258 Adenoviral infections Diseases 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 101100165660 Alternaria brassicicola bsc6 gene Proteins 0.000 description 1
- 101100499295 Bacillus subtilis (strain 168) disA gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000701106 Bovine adenovirus 3 Species 0.000 description 1
- 102100037084 C4b-binding protein alpha chain Human genes 0.000 description 1
- 101710159767 C4b-binding protein alpha chain Proteins 0.000 description 1
- 241000701157 Canine mastadenovirus A Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- OJIYIVCMRYCWSE-UHFFFAOYSA-M Domiphen bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1 OJIYIVCMRYCWSE-UHFFFAOYSA-M 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 241000807592 Fowl adenovirus Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 208000028523 Hereditary Complement Deficiency disease Diseases 0.000 description 1
- 101000837344 Homo sapiens T-cell leukemia translocation-altered gene protein Proteins 0.000 description 1
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000701244 Mastadenovirus Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- LYXFCGCYJQCSRL-UHFFFAOYSA-N OOSO Chemical compound OOSO LYXFCGCYJQCSRL-UHFFFAOYSA-N 0.000 description 1
- 101150007210 ORF6 gene Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 101100226894 Phomopsis amygdali PaGT gene Proteins 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 241000188845 Porcine adenovirus Species 0.000 description 1
- 101900083372 Rabies virus Glycoprotein Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102100028692 T-cell leukemia translocation-altered gene protein Human genes 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- NTGGOTYRTOXKMQ-UHFFFAOYSA-K aluminum;potassium;phosphate Chemical compound [Al+3].[K+].[O-]P([O-])([O-])=O NTGGOTYRTOXKMQ-UHFFFAOYSA-K 0.000 description 1
- 210000001776 amniocyte Anatomy 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000000852 deltoid muscle Anatomy 0.000 description 1
- 229960001859 domiphen bromide Drugs 0.000 description 1
- 108010067396 dornase alfa Proteins 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 238000012395 formulation development Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 101150088856 pix gene Proteins 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940107568 pulmozyme Drugs 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (15)
1. Sammensætning, der omfatter rekombinante adenoviruspartikler, hvor det rekombinante adenovirus omfatter et transgen og er et rekombinant humant adenovirus af serotype 5, 11a, 26, 34, 35, 49 eller 50 eller et rekombinant simian- adenovirus, der er kendetegnet ved, at genomerne i mindst 99 % af adenoviruspartiklerne i sammensætningen har nukleotidsekvensen: CTATCTAT som de 5'-terminale nukleotider.
2. Sammensætning ifølge krav 1, hvor det rekombinante adenovirus er et rekombinant humant adenovirus af serotype 5, 26, 35, 49 eller 50.
3. Sammensætning ifølge krav 2, hvor det rekombinante adenovirus er et rekombinant humant adenovirus af serotype 26 eller 35.
4. Sammensætning ifølge et hvilket som helst af ovennævnte krav, som er en farmaceutisk sammensætning.
5. Sammensætning ifølge et hvilket som helst af ovennævnte krav, hvor det rekombinante adenovirus mangler mindst en del af El-regionen.
6. Sammensætning ifølge et hvilket som helst af ovennævnte krav, der omfatter mindst 1 x 107, fortrinsvis mindst 1 x 108, fortrinsvis mindst 1 x 109, fortrinsvis mindst 1 x 1010 rekombinante adenoviruspartikler.
7. Fremgangsmåde til fremstilling af en batch af rekombinante adenoviruspartikler, hvor mindst 99 % af adenoviruspartiklerne i batchen har identiske nukleotidsekvenser i 5'-terminalerne af deres genomer, og hvor adenovirusset omfatter et transgen, hvilken fremgangsmåde omfatter: a) udførelse af et molekylært kloningstrin til udskiftning af de naturligt forekommende 5'-terminaler, som ikke er CTATCTAT, på et adenovirusgenom med ændrede 5'-terminaler, der omfatter nukleotidsekvensen: CTATCTAT som de terminale nukleotider, b) opformering i værtsceller af det rekombinante adenovirus med de ændrede 5'-terminaler og c) høst af det rekombinante adenovirus til opnåelse af en batch af rekombinante adenoviruspartikler, hvor mindst 99 % af adenoviruspartiklerne i batchen har nukleotidsekvensen: CTATCTAT som de 5'-terminale nukleotider af deres genomer.
8. Fremgangsmåde til fremstilling af en batch af rekombinante adenoviruspartikler, hvor mindst 99 % af adenoviruspartiklerne i batchen har identiske nukleotidsekvenser i 5'-terminalerne af deres genomer, og hvor adenovirusset omfatter et transgen, hvilken fremgangsmåde omfatter: a) udførelse af en plakoprensning af et adenovirus, hvor det rekombinante adenovirus er et rekombinant humant adenovirus af serotype 5, 11a, 26, 34, 35, 49 eller 50 eller et rekombinant simian-adenovirus, til isolering af et adenovirus eller rekombinant adenovirus fra en enkelt plak, hvor adenovirusset eller det rekombinante adenovirus har nukleotidsekvensen: CTATCTAT som de 5'-terminale nukleotider af dets genom, b) opformering i værtsceller af et rekombinant adenovirus, der er opnået fra den enkelte plak i trin a) , og c) høst af det rekombinante adenovirus til opnåelse af en batch af rekombinante adenoviruspartikler, hvor mindst 99 % of adenoviruspartiklerne i batchen har nukleotidsekvensen: CTATCTAT som de 5'-terminale nukleotider af deres genomer.
9. Fremgangsmåde ifølge krav 7 eller 8, hvor batchen omfatter mindst 1 x 107 rekombinante adenoviruspartikler.
10. Fremgangsmåde ifølge et hvilket som helst af kravene 7 til 9, hvor det rekombinante adenovirus er et rekombinant humant adenovirus af serotype 5, 26, 35, 49 eller 50.
11. Fremgangsmåde ifølge et hvilket som helst af kravene 7 til 10, hvor det rekombinante adenovirus er et rekombinant humant adenovirus af serotype 26 eller 35.
12. Fremgangsmåde ifølge et hvilket som helst af kravene 7 til 11, hvor det rekombinante adenovirus mangler mindst en del af El-regionen.
13. Fremgangsmåde ifølge et hvilket som helst af kravene 7 til 12, der yderligere omfatter oprensning af det rekombinante adenovirus.
14. Fremgangsmåde ifølge krav 13, der yderligere omfatter formulering af det rekombinante adenovirus til en farmaceutisk sammensætning.
15. Fremgangsmåde ifølge et hvilket som helst af kravene 7 til 14, hvor trin b) udføres i en bioreaktor.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261609678P | 2012-03-12 | 2012-03-12 | |
| EP12159009 | 2012-03-12 | ||
| PCT/EP2013/054846 WO2013135615A1 (en) | 2012-03-12 | 2013-03-11 | Batches of recombinant adenovirus with altered terminal ends |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2825640T3 true DK2825640T3 (da) | 2016-08-01 |
Family
ID=49160272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13708445.5T DK2825640T3 (da) | 2012-03-12 | 2013-03-11 | Batches af rekombinant adenovirus med ændrede terminale ender |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP2825640B1 (da) |
| JP (1) | JP5770952B2 (da) |
| KR (1) | KR102044051B1 (da) |
| CN (1) | CN104379733B (da) |
| AR (1) | AR090318A1 (da) |
| AU (1) | AU2013231423B2 (da) |
| CA (1) | CA2864956C (da) |
| DK (1) | DK2825640T3 (da) |
| EA (1) | EA034284B1 (da) |
| ES (1) | ES2582504T3 (da) |
| HU (1) | HUE027839T2 (da) |
| NZ (1) | NZ628385A (da) |
| PL (1) | PL2825640T3 (da) |
| SG (1) | SG11201405228VA (da) |
| SI (1) | SI2825640T1 (da) |
| TW (1) | TWI633188B (da) |
| WO (1) | WO2013135615A1 (da) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014236207B2 (en) | 2013-03-14 | 2019-05-23 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| JP6469081B2 (ja) | 2013-04-25 | 2019-02-13 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 安定化された可溶性融合前ｒｓｖｆポリペプチド |
| MY171210A (en) | 2013-06-17 | 2019-10-02 | Janssen Vaccines & Prevention Bv | Stabilized soluble pre-fusion rsv f polypeptides |
| KR20250081944A (ko) | 2014-09-24 | 2025-06-05 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양 살상 바이러스 및 이의 사용방법 |
| CN107847581B (zh) | 2015-07-07 | 2022-03-22 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
| ES2839880T3 (es) | 2015-07-07 | 2021-07-06 | Janssen Vaccines & Prevention Bv | Vacuna contra el VRS |
| GB201513010D0 (en) * | 2015-07-23 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel formulation |
| EP4155411A1 (en) | 2016-02-23 | 2023-03-29 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| WO2017147265A1 (en) * | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| PH12022552125A1 (en) | 2016-04-05 | 2023-04-12 | Janssen Vaccines & Prevention Bv | Stabilized soluble pre-fusion rsv f proteins |
| KR102500970B1 (ko) | 2016-04-05 | 2023-02-17 | 얀센 백신스 앤드 프리벤션 비.브이. | Rsv에 대한 백신 |
| CN109154000B (zh) * | 2016-05-12 | 2022-07-05 | 扬森疫苗与预防公司 | 有效和平衡的双向启动子 |
| IL264119B2 (en) | 2016-05-30 | 2023-04-01 | Janssen Vaccines Prevention B V | f proteins of rsv are stabilized before fusion |
| US10744196B2 (en) | 2016-07-14 | 2020-08-18 | Janssen Vaccines & Prevention B.V. | HPV vaccines |
| EP3532082A4 (en) | 2016-12-12 | 2020-08-26 | Salk Institute for Biological Studies | SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES |
| US11229692B2 (en) | 2017-05-17 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
| WO2019053109A1 (en) | 2017-09-15 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV |
| MX2020010499A (es) | 2018-04-09 | 2020-10-28 | Salk Inst For Biological Studi | Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion. |
| JP2022513025A (ja) | 2018-11-13 | 2022-02-07 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 安定化された融合前ｒｓｖ ｆタンパク質 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
| JP3816518B2 (ja) | 1994-06-10 | 2006-08-30 | ジェンベク、インコーポレイティッド | 相補的なアデノウイルスベクター系と細胞系 |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
| US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
| SI0833934T2 (sl) | 1995-06-15 | 2013-04-30 | Crucell Holland B.V. | Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji |
| US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
| US5891690A (en) | 1996-04-26 | 1999-04-06 | Massie; Bernard | Adenovirus E1-complementing cell lines |
| EP0944717A1 (fr) | 1996-07-01 | 1999-09-29 | Aventis Pharma S.A. | Procede de production d'adenovirus recombinants |
| FR2751343B1 (fr) | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
| WO1998010087A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| ES2278399T3 (es) | 1996-11-20 | 2007-08-01 | Introgen Therapeutics, Inc. | Metodo mejorado para la produccion y purificacion de vectores adenovirales. |
| US6261823B1 (en) | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
| CA2283253A1 (en) | 1997-03-04 | 1998-09-11 | Baxter International Inc. | Adenovirus e1-complementing cell lines |
| US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
| US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
| KR100912362B1 (ko) | 1998-02-17 | 2009-08-19 | 쉐링 코포레이션 | 바이러스 제제의 정제방법 |
| US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
| US6670188B1 (en) | 1998-04-24 | 2003-12-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
| DE69940354D1 (de) | 1998-11-16 | 2009-03-12 | Introgen Therapeutics Inc | Adenovirus-formulierungen zur gentherapie |
| US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
| ATE519855T1 (de) | 1999-05-17 | 2011-08-15 | Crucell Holland Bv | Rekombinantes adenovirus des serotyps ad11 |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| CA2378539A1 (en) | 1999-07-06 | 2001-01-11 | Merck & Co., Inc. | Adenovirus carrying gag gene hiv vaccine |
| DE19955558C2 (de) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
| EP2420247A1 (en) | 2000-03-07 | 2012-02-22 | Merck Sharp & Dohme Corp. | Adenovirus formulations |
| CA2422882A1 (en) | 2000-09-15 | 2002-03-21 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications |
| EP1453536A4 (en) | 2001-12-12 | 2009-08-26 | Mayne Pharma Int Pty Ltd | COMPOSITION FOR PRESERVING VIRUSES |
| AR038153A1 (es) | 2002-01-18 | 2004-12-29 | Schering Ag | Formulaciones estabilizadas de adenovirus |
| US20030180936A1 (en) | 2002-03-15 | 2003-09-25 | Memarzadeh Bahram Eric | Method for the purification, production and formulation of oncolytic adenoviruses |
| KR101021387B1 (ko) | 2002-04-25 | 2011-03-14 | 크루셀 홀란드 비.브이. | 아데노바이러스 벡터를 생산하기 위한 수단 및 방법 |
| DK1497440T3 (da) | 2002-04-25 | 2008-12-01 | Crucell Holland Bv | Stabile adenovirale vektorer og fremgangsmåder til propagering deraf |
| DE60335672D1 (de) | 2002-05-14 | 2011-02-17 | Merck Sharp & Dohme | Verfahren zur reinigung von adenovirus |
| SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
| CA2496918A1 (en) | 2002-08-28 | 2004-03-11 | Introgen Therapeutics Inc. | Chromatographic methods for adenovirus purification |
| EP1553983A2 (en) | 2002-10-23 | 2005-07-20 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
| WO2004055187A1 (en) | 2002-12-17 | 2004-07-01 | Crucell Holland B.V. | Recombinant viral-based malaria vaccines |
| SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
| ATE449105T1 (de) | 2004-01-23 | 2009-12-15 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
| NZ548495A (en) | 2004-02-23 | 2009-05-31 | Crucell Holland Bv | Virus purification methods |
| US7510868B2 (en) * | 2004-05-26 | 2009-03-31 | Paul Harden | Chimeric adenoviruses for use in cancer treatment |
| SG159555A1 (en) | 2004-11-16 | 2010-03-30 | Crucell Holland Bv | Multivalent vaccines comprising recombinant viral vectors |
| DK1869171T4 (da) | 2005-04-11 | 2016-01-18 | Crucell Holland Bv | Virusrensning under anvendelse af ultrafiltrering |
| TW200716750A (en) | 2005-05-12 | 2007-05-01 | Glaxo Group Ltd | Vaccine composition |
| US20100143302A1 (en) | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
| US20090110695A1 (en) | 2006-03-27 | 2009-04-30 | Menzo Jans Emko Havenga | Compositions Comprising a Recombinant Adenovirus and an Adjuvant |
| JP5448840B2 (ja) * | 2006-12-22 | 2014-03-19 | プシオクサス・セラピューティクス・リミテッド | 腫瘍退縮アデノウイルスの作出およびその使用 |
| WO2009026183A1 (en) | 2007-08-17 | 2009-02-26 | The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services | Use of chimeric hiv/siv gag proteins to optimize vaccine-induced t cell responses against hiv gag |
| WO2009117134A2 (en) | 2008-03-21 | 2009-09-24 | National Institutes Of Health | Aerosolized genetic vaccines and methods of use |
| CN102203242B (zh) | 2008-11-03 | 2013-06-12 | 克鲁塞尔荷兰公司 | 产生腺病毒载体的方法 |
| WO2010085984A1 (en) | 2009-02-02 | 2010-08-05 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| EP2391638B1 (en) | 2009-02-02 | 2018-06-27 | GlaxoSmithKline Biologicals SA | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| WO2010096561A1 (en) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
| CN102575233B (zh) | 2009-10-15 | 2014-07-16 | 克鲁塞尔荷兰公司 | 从高细胞密度培养物纯化腺病毒的方法 |
| EA028623B1 (ru) | 2009-10-15 | 2017-12-29 | Янссен Вэксинс Энд Превеншн Б.В. | Способ очистки аденовирусных частиц |
| MX2012007936A (es) | 2010-02-15 | 2012-11-22 | Crucell Holland Bv | Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus. |
-
2013
- 2013-03-11 JP JP2014561393A patent/JP5770952B2/ja active Active
- 2013-03-11 NZ NZ628385A patent/NZ628385A/en not_active IP Right Cessation
- 2013-03-11 SG SG11201405228VA patent/SG11201405228VA/en unknown
- 2013-03-11 EA EA201491676A patent/EA034284B1/ru not_active IP Right Cessation
- 2013-03-11 SI SI201330239A patent/SI2825640T1/sl unknown
- 2013-03-11 PL PL13708445.5T patent/PL2825640T3/pl unknown
- 2013-03-11 CN CN201380013551.5A patent/CN104379733B/zh active Active
- 2013-03-11 CA CA2864956A patent/CA2864956C/en active Active
- 2013-03-11 WO PCT/EP2013/054846 patent/WO2013135615A1/en not_active Ceased
- 2013-03-11 EP EP13708445.5A patent/EP2825640B1/en active Active
- 2013-03-11 HU HUE13708445A patent/HUE027839T2/en unknown
- 2013-03-11 AU AU2013231423A patent/AU2013231423B2/en not_active Ceased
- 2013-03-11 KR KR1020147026543A patent/KR102044051B1/ko not_active Expired - Fee Related
- 2013-03-11 ES ES13708445.5T patent/ES2582504T3/es active Active
- 2013-03-11 DK DK13708445.5T patent/DK2825640T3/da active
- 2013-03-12 TW TW102108773A patent/TWI633188B/zh not_active IP Right Cessation
- 2013-03-12 AR ARP130100798A patent/AR090318A1/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013231423B2 (en) | 2018-10-04 |
| CN104379733B (zh) | 2016-01-20 |
| EA201491676A1 (ru) | 2014-12-30 |
| CA2864956A1 (en) | 2013-09-19 |
| ES2582504T3 (es) | 2016-09-13 |
| JP2015511597A (ja) | 2015-04-20 |
| AR090318A1 (es) | 2014-11-05 |
| SG11201405228VA (en) | 2014-11-27 |
| SI2825640T1 (sl) | 2016-08-31 |
| AU2013231423A1 (en) | 2014-08-28 |
| EA034284B1 (ru) | 2020-01-24 |
| EP2825640B1 (en) | 2016-04-27 |
| NZ628385A (en) | 2016-09-30 |
| KR102044051B1 (ko) | 2019-11-12 |
| TWI633188B (zh) | 2018-08-21 |
| CA2864956C (en) | 2021-11-09 |
| EP2825640A1 (en) | 2015-01-21 |
| KR20140139509A (ko) | 2014-12-05 |
| CN104379733A (zh) | 2015-02-25 |
| JP5770952B2 (ja) | 2015-08-26 |
| PL2825640T3 (pl) | 2016-10-31 |
| HUE027839T2 (en) | 2016-11-28 |
| TW201336993A (zh) | 2013-09-16 |
| WO2013135615A1 (en) | 2013-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2825640T3 (da) | Batches af rekombinant adenovirus med ændrede terminale ender | |
| US8932607B2 (en) | Batches of recombinant adenovirus with altered terminal ends | |
| US11781155B2 (en) | Potent and balanced bidirectional promoter | |
| JP6735288B2 (ja) | 双方向性プロモーターを有する２つの導入遺伝子を発現する組換えアデノウイルス | |
| US20230279425A1 (en) | Potent and balanced bidirectional promoter | |
| HK1206385B (en) | Batches of recombinant adenovirus with altered terminal ends |